A message from our friends at Base Camp Trading (Sponsor) |
Good Morning Trade Setup... Done By 10AM |
Hey Trader, |
Before the market opens again, read this... |
My top trader, Thomas Wood, just released a new strategy he calls Opening Bell Trades. |
This simple system is designed specifically to help regular investors generate income from his #1 trade setup. |
I'm talking about finding monster winners like these... |
113% on GOOGL 240% on META 70% on CAG 37% on MCD 139% on GLD
|
Best of all, he looks for these trades every morning starting at 9:30 AM and by 10 he's done. |
Everything you need to know about how this works is in a free report called "The Opening Bell Trade Guide"... |
Take a few seconds and download FREE right now before this link stops working. |
This report won't be free forever, so grab it now while you can. |
Once it's on your computer, you'll have it for good-no matter what we charge other traders for it later. |
No credit card required. No strings attached. |
>> Get Your COMPLIMENTARY "Opening Bell Breakouts" Trade Guide Here |
This guide shows you the exact 15-minute window trade he uses, and how to spot the setups the big funds are watching. |
COMPLIMENTARY: Discover One Simple Options Trade You Can Make Each Morning – and Be Done by 10 AM. |
To better trading, |
Drew Day
Founder & CEO
Base Camp Trading |
P.S. Inside, you'll see why Thomas uses weekly options and how to use them to trade stocks like GOOGL, META, and TSLA with as little as $75. Go here to save a copy of the "Opening Bell Trade Guide" before its taken down. |
|
BONUS ARTICLE |
The Ozempic Distribution Trade: Why Hims & Hers (HIMS) Just Became the Market's Most Viral Healthcare Stock |
Every once in a while the market gives you a move so violent it forces investors to ask a deeper question. |
Not "Why did the stock go up?" |
But rather: |
"What just changed about the business?" |
That is the situation with Hims & Hers (HIMS) today. |
The stock exploded more than 44% after reports that Novo Nordisk plans to distribute its blockbuster weight-loss drugs through the Hims telehealth platform. |
That headline instantly pushed HIMS to the #1 trending ticker on both X and Stocktwits. |
But the real reason investors are paying attention is not social media. |
It's the math. |
Because the weight-loss drug market is quickly becoming one of the largest pharmaceutical opportunities in history. |
And the companies controlling distribution and patient access could end up capturing an enormous share of that growth. |
|
The Market Temperature: The $100 Billion Drug Category |
To understand why this news matters, you need to understand the scale of the GLP-1 market. |
The blockbuster drugs driving this revolution include: |
Wegovy (Novo Nordisk) Ozempic (Novo Nordisk) Zepbound (Eli Lilly) Mounjaro (Eli Lilly)
|
These drugs mimic a hormone called GLP-1, which regulates appetite and insulin levels. |
Clinical trials have shown patients losing 15–22% of body weight using these medications. |
The demand has been staggering. |
Key numbers: |
• Novo Nordisk generated $33+ billion in revenue in 2024, with GLP-1 drugs accounting for a majority of growth.
• Wegovy and Ozempic alone produced over $18 billion combined annual revenue.
• Eli Lilly's Zepbound and Mounjaro are expected to reach $20+ billion annually at peak sales. |
Most analysts now estimate the global obesity drug market could exceed $100 billion per year by the early 2030s. |
That would make it larger than many entire pharmaceutical sectors. |
But here is the catch: |
Demand is outpacing distribution capacity. |
And that is where Hims & Hers enters the story. (continued below…) |
A $7 Billion Neighbor - And an Explorer Under $1(sponsor) |
|
In the same district as a $7B mining company, a smaller U.S. explorer is advancing its assets while still trading under $1. Copper is strengthening while supply is tight. It may not be long before the market begins to notice this budding neighbor.
|
Meet the Neighbor Turning Heads >
|
|
(…continues) |
Company Profile: What Hims & Hers Actually Is |
Hims & Hers is not a pharmaceutical company. |
It does not manufacture drugs. |
Instead, it operates a direct-to-consumer telehealth platform that connects patients with doctors and delivers prescriptions through mail-order pharmacies. |
The model works like this: |
Patients complete an online medical questionnaire. A licensed healthcare provider reviews the case. Prescriptions are issued digitally. Medications are shipped directly to the patient.
|
This system eliminates many traditional barriers in healthcare: |
• doctor appointment delays
• pharmacy visits
• insurance friction
• geographic limitations |
That convenience has helped Hims grow extremely quickly. |
Key financial numbers: |
• 2023 revenue: $872 million
• 2024 revenue estimate: ~$1.2 billion
• Active subscribers: ~1.7 million
• Gross margin: ~80%
• Annual revenue growth: roughly 45–50% |
In other words, the company already had strong growth before the GLP-1 opportunity. |
|
The Catalyst: Plugging HIMS Into the Weight-Loss Gold Rush |
The report that triggered today's surge suggests Novo Nordisk could sell its drugs through the Hims telehealth ecosystem. |
That matters for two reasons. |
1. Patient Acquisition |
Millions of Americans are trying to access GLP-1 drugs. |
Current estimates suggest over 40 million U.S. adults could qualify for medical weight-loss treatments. |
Traditional healthcare infrastructure cannot process that demand quickly. |
Telehealth platforms can. |
If even 2% of that population used Hims, that would represent: |
800,000 potential patients. |
At current GLP-1 pricing levels of $800–$1,300 per month, that represents $7.6B to $12.4B annual drug flow through the platform. |
Even if Hims captured only 5–10% distribution margins, the revenue potential becomes enormous. |
|
2. Platform Economics |
Telehealth companies monetize in several ways: |
• consultation fees
• subscription memberships
• pharmacy fulfillment
• recurring prescriptions |
GLP-1 treatments are long-term therapies. |
Patients often remain on the drugs for multiple years. |
That means the platform could benefit from recurring monthly revenue streams. |
If Hims captured just 300,000 GLP-1 patients, and earned an average $100 monthly platform fee, that would generate: |
$360 million annual incremental revenue. |
That would increase total company revenue by roughly 30–40% immediately. |
And that scenario assumes only modest penetration. |
|
Why Investors Reacted So Aggressively |
The stock's 44% surge reflects something deeper than hype. |
Markets immediately recognized that this partnership changes how investors should value Hims & Hers. |
Before the announcement, Hims was seen primarily as a consumer telehealth company selling treatments for: |
• hair loss
• erectile dysfunction
• dermatology
• mental health |
Those are valuable but relatively niche categories. |
The GLP-1 market is different. |
It's one of the largest medical demand shocks in decades. |
If Hims becomes a primary access channel for these drugs, the company transitions from a niche telehealth platform into a major digital healthcare gateway. |
That is a very different valuation story. |
|
The Competitive Landscape |
Of course, this opportunity will not belong exclusively to Hims. |
Several companies are competing to become the "front door" for digital healthcare: |
• Ro
• Teladoc
• Amazon Clinic
• traditional pharmacy chains |
But Hims currently has several advantages: |
A strong consumer brand A large existing subscriber base Direct-to-consumer marketing expertise A vertically integrated telehealth + pharmacy model
|
That infrastructure allows the company to scale faster than many competitors. |
|
|
The Valuation Question |
After today's surge, investors must ask whether the opportunity is already priced into the stock. |
Even after the rally, Hims' market cap sits around $4–5 billion. |
If the company eventually generates $2–3 billion in annual revenue, a growth-tech multiple could justify a significantly higher valuation. |
But the key variable is execution. |
This story depends on several factors: |
• actual Novo Nordisk distribution agreements
• regulatory approval pathways
• telehealth prescription rules
• competition from other platforms |
If those elements align, Hims could become one of the most important digital healthcare distribution networks. |
If not, the current excitement could fade quickly. |
|
Bull, Base, Bear |
Bull Case |
GLP-1 prescriptions surge through telehealth platforms, Hims captures a major share of the distribution pipeline, and revenue growth accelerates above 50% annually. |
Base Case |
The partnership increases user growth, but competition limits margins and the stock stabilizes after the initial rally. |
Bear Case |
Regulatory hurdles or competitive platforms limit Hims' access to GLP-1 supply, causing the growth narrative to cool. |
|
Cheap Investor Playbook |
Cheap Investors do not chase 40% moves blindly. |
The smarter strategy is to watch post-announcement behavior. |
Key signals to monitor: |
Confirmation of Novo Nordisk distribution agreements Subscriber growth tied to weight-loss treatments Quarterly revenue acceleration above current forecasts Institutional accumulation following the breakout
|
If those indicators confirm the thesis, the market may begin pricing Hims as a digital healthcare infrastructure company rather than a niche telehealth platform. |
|
Bottom Line |
Hims & Hers did not just become a viral stock today. |
It became a company suddenly connected to one of the largest pharmaceutical markets in the world. |
If the GLP-1 distribution story proves real, the company could sit at the intersection of three powerful trends: |
• digital healthcare
• obesity drug demand
• direct-to-consumer medical distribution |
And when a small company plugs into a $100 billion market, the market tends to notice. |
Which explains why HIMS just had one of the biggest moves in the entire market. |
The real question now is not whether the stock can move. |
It's whether the business can grow fast enough to justify the excitement. |
|
Disclaimer: This editorial is for informational purposes only and should not be considered investment advice. Always conduct independent research before making financial decisions. |
Tidak ada komentar:
Posting Komentar